利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

46 records (took 0.026 seconds)

    ORAL CARE COMPOSITIONS AND METHODS
    21.
    发明申请
    ORAL CARE COMPOSITIONS AND METHODS 审中-公开
    口腔护理组合物和方法

    公开(公告)号：US20130039865A1

    公开(公告)日：2013-02-14

    申请号：US13574095

    申请日：2011-01-19

    Applicant: Edward R. Truitt, III ,  Benjamin Sullivan ,  Nicholas Tennison

    Inventor： Edward R. Truitt, III ,  Benjamin Sullivan ,  Nicholas Tennison

    IPC: A61K8/64 ,  A61Q11/00 ,  A61K8/73

    CPC classification number: A61K38/1709

    Abstract: Provided herein is a pharmaceutical or oral care product for treating or preventing oral diseases that is prepared with proteoglycan 4 (PRG4) as an active ingredient, the preparing method thereof and the use thereof in manufacturing medicaments or oral care products for treating or preventing oral diseases and maintenance of oral health. PRG4 may have efficacy in maintaining oral health and treating or preventing oral disease. This secreted glycoprotein, which is also called lubricin and superficial zone protein, is known to protect against frictional forces, cell adhesion and protein deposition.

    Abstract translation: 本文提供了用于治疗或预防用蛋白多糖4（PRG4）作为活性成分制备的口腔疾病的药物或口腔护理产品，其制备方法及其在制备用于治疗或预防口腔疾病的药物或口腔护理产品中的用途 并维持口腔健康。 PRG4可能具有维持口腔健康和治疗或预防口腔疾病的功效。 已知这种分泌的糖蛋白也称为润滑剂和表面区蛋白，以防止摩擦力，细胞粘附和蛋白质沉积。

    Methods, Systems and Platform Devices for Aggregating Together Users of a TVand/or an Interconnected Network
    23.
    发明申请
    Methods, Systems and Platform Devices for Aggregating Together Users of a TVand/or an Interconnected Network 审中-公开
    用于聚合TV和/或互连网络的用户的方法，系统和平台设备

    公开(公告)号：US20110154224A1

    公开(公告)日：2011-06-23

    申请号：US12970062

    申请日：2010-12-16

    Applicant: Dan Bates ,  Scott Holmes ,  Benjamin Sullivan

    Inventor： Dan Bates ,  Scott Holmes ,  Benjamin Sullivan

    IPC: G06F3/01 ,  G06F15/16

    CPC classification number: G06Q10/10 ,  H04L12/1822 ,  H04N21/4788 ,  H04N21/812

    Abstract: Described herein are methods, systems, and devices comprising or utilizing a digital processing device comprising an operating system that is configured to read executable instructions for creating at least one contextual-based chatroom that is focused on a topic of interest that is in common between at least a first user (including e.g., a pulled or pushed user) and at least a second user (including e.g., a pulled or pushed user) of an interconnected network.

    Abstract translation: 这里描述了包括或利用数字处理设备的方法，系统和设备，该数字处理设备包括操作系统，该操作系统被配置为读取可执行指令，用于创建至少一个基于语境的聊天室，该聊天室专注于感兴趣的主题， 至少一个第一用户（包括例如，被拉或被推的用户）和至少一个互连网络的第二用户（包括例如拉或被推的用户）。

    Therapeutic Replenishment and Enrichment of Ocular Surface Lubrication
    24.
    发明申请
    Therapeutic Replenishment and Enrichment of Ocular Surface Lubrication 有权
    治疗补充和丰富的眼表润滑

    公开(公告)号：US20110059902A1

    公开(公告)日：2011-03-10

    申请号：US12940370

    申请日：2010-11-05

    Applicant: Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

    Inventor： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

    IPC: A61K38/17 ,  A61P27/02

    CPC classification number: A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

    Abstract translation: 本发明提供了一种药物组合物及其使用方法，用于治疗眼部边界不足，与之相关的症状，或与眼表面相关或导致眼部边界缺陷的不期望状况。 本发明的药物组合物包含悬浮在眼科可接受的平衡盐溶液中的人PRG4蛋白，润滑剂片段，同系物或同种型。 本发明的药物组合物还可以包含一种或多种选自以下的眼科学上可接受的试剂：药学上可接受的药物，所述药剂选自眼科可接受的抑制剂，赋形剂，收敛剂，血管收缩剂，润肤剂，透明质酸钠，透明质酸和表面活性磷脂 载体用于局部给药。

    BIOMARKER NORMALIZATION
    30.
    发明申请
    BIOMARKER NORMALIZATION 有权
    生物标志正常化

    公开(公告)号：US20080264152A1

    公开(公告)日：2008-10-30

    申请号：US12104355

    申请日：2008-04-16

    Applicant: Benjamin Sullivan

    Inventor： Benjamin Sullivan

    IPC: G01N13/04

    CPC classification number: G01N13/04 ,  B01L3/502715 ,  B01L2300/0654 ,  G01N21/6486 ,  G01N27/07 ,  G01N27/26 ,  G01N33/487 ,  G01N2800/162 ,  G01N2800/24 ,  G06F19/24

    Abstract: In accordance with the invention, a fluid sample is measured with a tear film measuring system that includes a processing device that receives a sample chip comprising a sample region configured to contain an aliquot volume of sample fluid, the processing device configured to perform analyses of osmolarity and of one or more biomarkers within the sample fluid, wherein the analysis of biomarkers includes normalization of biomarker concentration values.

    Abstract translation: 根据本发明，用泪液测量系统测量流体样品，所述泪液测量系统包括处理装置，所述处理装置接收包含样品区域的样品芯片，该样品区域被配置为容纳等分试样体积的样品流体，所述处理装置被配置为进行渗透压分析 和样品液体中的一种或多种生物标志物，其中生物标志物的分析包括生物标志物浓度值的归一化。

Patent Agency Ranking